Advertisement
Research ArticleArticle

Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury

Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong and Xiaoyan Chen
Drug Metabolism and Disposition November 2015, 43 (11) 1751-1759; DOI: https://doi.org/10.1124/dmd.115.064121

Abstract

Fasiglifam (TAK-875), a selective G-protein–coupled receptor 40 agonist, was developed for the treatment of type 2 diabetes mellitus; however, its development was terminated in phase III clinical trials because of liver safety concerns. Our preliminary study indicated that intravenous administration of 100 mg/kg of TAK-875 increased the serum total bile acid concentration by 3 to 4 times and total bilirubin levels by 1.5 to 2.6 times in rats. In the present study, we examined the inhibitory effects of TAK-875 on hepatobiliary transporters to explore the mechanisms underlying its hepatotoxicity. TAK-875 decreased the biliary excretion index and the in vitro biliary clearance of d8-taurocholic acid in sandwich-cultured rat hepatocytes, suggesting that TAK-875 impaired biliary excretion of bile acids, possibly by inhibiting bile salt export pump (Bsep). TAK-875 inhibited the efflux transporter multidrug resistance-associated protein 2 (Mrp2) in rat hepatocytes using 5 (and 6)-carboxy-2′,7′-dichlorofluorescein as a substrate. Inhibition of MRP2 was further confirmed by reduced transport of vinblastine in Madin-Darby canine kidney cells overexpressing MRP2 with IC50 values of 2.41 μM. TAK-875 also inhibited the major bile acid uptake transporter Na+/taurocholate cotransporting polypeptide (Ntcp), which transports d8-taurocholic acid into rat hepatocytes, with an IC50 value of 10.9 μM. TAK-875 significantly inhibited atorvastatin uptake in organic anion transporter protein (OATP) 1B1 and OATP1B3 cells with IC50 values of 2.28 and 3.98 μM, respectively. These results indicate that TAK-875 inhibited the efflux transporter MRP2/Mrp2 and uptake transporters Ntcp and OATP/Oatp, which may affect bile acid and bilirubin homeostasis, resulting in hyperbilirubinemia and cholestatic hepatotoxicity.

Introduction

Fasiglifam (TAK-875, Fig. 1) is an orally available, potent, and selective partial agonist of G-protein–coupled receptor 40 (GPR40) that was developed for the treatment of type 2 diabetes mellitus (Negoro et al., 2010). TAK-875 markedly improves glycemic control via its glucose-dependent mechanism of action, which made it a promising candidate for the treatment of type 2 diabetes mellitus, together with its low risk of hypoglycemia compared with classic insulin secretagogues. However, the clinical development of TAK-875 was unexpectedly terminated at phase III clinical trials owing to concerns about its liver safety (http://www.takeda.com/news/2013/20131227_6117.html). The mechanism by which TAK-875 caused liver injury still remains unclear.

Fig. 1.
Fig. 1.

Chemical structure of TAK-875.

After a single oral administration of 50 mg of TAK-875 to healthy subjects, TAK-875 was rapidly absorbed with median time to the maximum concentration (i.e. tmax) ranging from 3 to 4 hours (Naik et al., 2012). The maximum plasma drug concentration (i.e. Cmax) and the area under the plasma concentration–time curve from zero to infinity (i.e. AUC0-∞) were 2.3 μg/ml and 44.2 μg·h/ml, respectively (Naik et al., 2012). The mean percent unbound TAK-875 values in plasma were 0.17% in subjects with normal renal function (Mayer et al., 2014). The elimination of TAK-875 from the systemic circulation was relatively slow, with a mean terminal elimination half-life (i.e. t1/2) of approximately 28.1–36.6 hours (Naik et al., 2012). Furthermore, TAK-875 exhibited a longer t1/2 (31–51 hours) in diabetic patients than in healthy subjects, increasing accumulation by 2.4–3.6 times in diabetic patients (Leifke et al., 2012). After 14 days of once-daily dosing of 50 mg TAK-875 in subjects with type 2 diabetes, the mean steady-state plasma concentration was 5.3 μg/ml (about 10.1 μM) (Leifke et al., 2012). The negligible urinary excretion values for TAK-875 (≤0.3%) suggested that nonrenal clearance, including hepatic metabolism, was the predominant route of elimination (Naik et al., 2012). Our preliminary studies indicated that after an intravenous administration of 100 mg/kg of TAK-875 to rats, TAK-875 exhibited high concentrations even at 24 hours postdose (Supplemental Fig. 1; Supplemental Table 1) and the parent drug was the major related compound in circulation (Supplemental Fig. 2). The tissue disposition of TAK-875 in rats showed that its concentration was about 3 times greater in the liver than in plasma. If this liver-plasma ratio observed in rat was representative of humans, the concentration of TAK-875 in liver was expected to be about 30 μM after multiple doses of 50 mg TAK-875 to subjects with type 2 diabetes.

Our preliminary study also showed that the serum total bile acids (TBAs) and total bilirubin (conjugated and unconjugated, TBIL) level were increased in rats after an intravenous dose of 100 mg/kg of TAK-875. It was reported that increased serum total bile acid and conjugated bilirubin concentrations are indicators of cholestasis, which accounts for approximately 30% of all cases of drug-induced liver injury (Zamek-Gliszczynski et al., 2012). Bile acids are predominantly taken up from the sinusoidal blood into hepatocytes by the uptake transporter Na+/taurocholate cotransporting polypeptide (NTCP in humans/Ntcp in rodents) in a Na+-dependent manner (Meier et al., 1997; Trauner and Boyer, 2003; Dawson et al., 2009). Organic anion transporting proteins (OATPs in humans/Oatps in rodents) are also involved in the hepatic uptake of bile acids in a Na+-independent manner (Jacquemin et al., 1994; Satlin et al., 1997; Cui et al., 2001; Alrefai and Gill, 2007). After binding to intracellular binding proteins, bile acids are primarily secreted into the canaliculus via the bile salt export pump (BSEP in humans/Bsep in rodents) and multidrug resistance-associated protein (MRP in humans/Mrp in rodents) 2 on the canalicular membrane (Kock and Brouwer, 2012). Bilirubin, the degradation product of heme from red blood cells, is taken up into hepatocytes by members of the OATP/Oatp family, followed by conjugation with glucuronic acid to bilirubin-glucuronide and bilirubin-diglucuronide (Cui et al., 2001). These conjugated bilirubin glucuronides are excreted mainly into bile by MRP2/Mrp2 (Chang et al., 2013).

The increase in serum TBA and TBIL concentrations may be associated with the inhibition of basolateral uptake transporters or canalicular efflux transporters. Because TAK-875 accumulates over a long time and reaches high concentrations in the liver, it may interfere with the transport of bile acids and bilirubin. Therefore, the aims of the present study were to investigate the effects of TAK-875 on the hepatobiliary disposition of bile acids and bilirubin in sandwich-cultured rat hepatocytes (SCRHs) and recombinant cell lines overexpressing OATP and MRP2 and to explore the potential mechanisms for drug-induced liver injury.

Materials and Methods

Materials.

The reference standard of TAK-875 was purchased from Shanghai Biochempartner Co. Ltd. (Shanghai, China). Rifampicin, atorvastatin calcium, MK-571, cyclosporine A (CyA), dexamethasone, 5 (and 6)-carboxy-2′,7′-dichlorofluorescein diacetate (CDFDA), and Hanks’ balanced salt solution (HBSS, pH 7.4) were obtained from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM), l-glutamine, minimum essential medium nonessential amino acids, penicillin G, and streptomycin were supplied by Invitrogen (Carlsbad, CA). d8-Taurocholic acid (d8-TCA) was purchased from Martrex, Inc. (Minnetonka, MN). Cholic acid (CA), deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), TCA, taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA), and glycoursodeoxycholic acid (GUDCA) were purchased from Toronto Research Chemicals (TRC), Inc. (North York, ON, Canada). ITS+, Matrigel, and 24-well plates biocoated with collagen I or poly-D-lysine were obtained from BD Biosciences (San Jose, CA). Human embryonic kidney (HEK293) cells were individually transfected with human (h)OATP1B1, hOATP1B3, hOATP2B1, and a control vector (mock-transfected cells), and the functions of these transporters were validated using positive substrates and inhibitors. Madin-Darby canine kidney (MDCK) cells overexpressing MRP2 (MDCK-MRP2 cells) (Li et al., 2012) were a kind gift from Prof. Zhong Zuo (The Chinese University of Hong Kong, Hong Kong, China). The assay kits of total bile acid (TBA), alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were purchased from Nanjing Jiancheng Bioengineering Institute (Jiangsu, China). The bicinchoninic acid (BCA) protein assay kit was purchased from Beyotime (Jiangsu, China). Deionized water was generated using a Millipore Milli-Q Gradient Water Purification System (Molsheim, France). All other solvents and reagents were of either high-performance liquid chromatography (HPLC) or analytical grade.

In Vivo Cholestatic Effects in Rats.

All procedures involving animals were performed in accordance with Guide for the Care and Use of Laboratory Animals at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Male Sprague-Dawley rats weighing 200–250 g were fasted overnight before the experiments and were randomized into two groups (six rats per group). Rats were given an intravenous administration of 20 or 100 mg/kg TAK-875 or saline as a control. Blood samples were collected before and at 15, 30, 45 minutes and 1, 2, 4, 8, and 24 hours after the dose of TAK-875 or vehicle. Serum samples were obtained by centrifugation of blood samples at 3500 rpm for 5 minutes after blood samples standing for 30 minutes. Serum TBA, ALT, ALP, and AST concentrations were determined using the corresponding assay kits in accordance with the manufacturer’s instructions. The TBIL was measured using Hitachi 7060 automatic biochemical analyzer (Hitachi High-Technologies Co., Tokyo, Japan). The concentrations of 11 BAs in rat serum at predose and 1 hour postdose were determined using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

Isolation and Culture of Rat Primary Hepatocytes.

Hepatocytes from male Sprague-Dawley rats were isolated by the two-step collagenase digestion method as previously described (Annaert et al., 2001). The viability of the obtained hepatocytes was determined using trypan blue exclusion method and was routinely >90%. Rat hepatocytes were seeded onto collagen I-coated 24-well plates at a density of 3.0 × 105 cells/well and cultured in Williams’ E medium supplemented with 0.1 μM dexamethasone, 5% FBS, 100 U penicillin, 100 μg/ml streptomycin, 2 mM glutamine, and 1% ITS+. After incubation for 4 hours at 37°C under 5% CO2 and 95% humidity, the medium was replaced with serum-free medium. After incubation for 24 hours, the hepatocytes were overlaid with 0.25 mg/ml of ice-cold Matrigel to form sandwich configuration, and culture medium was thereafter replaced every 24 hours. Rat hepatocytes cultured for 4 hours could be used for the transporter-mediated uptake assays.

Hepatobiliary Disposition of d8-TCA/CDFDA in SCRH.

The uptake studies were conducted on day 4 of culture. Hepatocytes were rinsed three times with either prewarmed standard HBSS or Ca2+-free HBSS, and then hepatocytes were incubated with the same buffer either in the presence or absence of the test compound (20 or 100 μM TAK-875, 20 μM MK-571, or 10 μM CyA) for 10 minutes at 37°C. Incubation in standard buffer maintains the integrity of the tight junctions, whereas incubation in Ca2+-free buffer opens the tight junctions. After the initial incubation, the incubation buffer was replaced with regular HBSS containing the test compounds. After incubation for 10 minutes, the hepatocytes were quickly rinsed three times with the ice-cold standard buffer. The accumulation of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein (CDF) in bile canaliculi was visualized under a fluorescence microscope (Olympus, Tokyo, Japan). Rat hepatocytes treated with d8-TCA were lysed with 200 μl deionized water by three freeze-thaw cycles, and the samples were stored at −20°C until analysis. The concentration of d8-TCA was measured by LC-MS/MS analysis as described subsequently herein. Protein concentrations were determined using a BCA protein assay kit.

d8-TCA Uptake Inhibition Assay.

After freshly isolated rat hepatocytes were cultured for 4 hours, the cells could be used for uptake assays. To investigate the effects of TAK-875 on Na+-dependent uptake of d8-TCA into rat hepatocytes, the Na+ in standard HBSS buffer was replaced with choline chloride. The cells were rinsed three times with standard HBSS or choline buffer and equilibrated in the same buffer with or without inhibitors (100 μM CyA, and 0–50 μM TAK-875) for 10 minutes. The uptake study was then initiated by adding standard HBSS containing d8-TCA, with or without the indicated inhibitors. The uptake was terminated after 5 minutes, and the cells were quickly rinsed three times with ice-cold HBSS. The cells were lysed by adding 200 μl of deionized water followed by three freeze-thaw cycles. The samples were stored at −20°C until analysis. The concentration of d8-TCA was determined using LC-MS/MS method as described below. The protein concentration was determined using a BCA assay kit.

OATP Inhibition Assay.

OATP1B1-, OATP1B3-, OATP2B1-, and mock-transfected HEK293 cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U penicillin G, 100 μg/ml streptomycin, and 1% minimum essential medium nonessential amino acids at 37°C in a humidified 5% CO2 atmosphere. Cells were seeded on poly-d-lysine–coated 24-well plates at a density of 2 × 105 cells/well. Uptake studies were performed on day 3 of culture. The cells were first washed three times with prewarmed HBSS (pH 7.4). After preincubation with HBSS in the presence or absence of various concentrations of TAK-875 for 10 minutes at 37°C, the equilibration buffer was removed and uptake was initiated by adding HBSS containing the substrate atorvastatin (0.3 μM) with or without TAK-875. The uptake was terminated at the designated time by aspirating the incubation solution and washing the cells three times with ice-cold HBSS. The cells were lysed by adding 200 μl of deionized water followed by three freeze-thaw cycles. The protein content of the cell lysate was determined using a BCA protein assay kit. The concentrations of atorvastatin were determined by LC-MS/MS.

MRP2 Inhibition Assay.

MDCK-MRP2 cells were cultured as described above for HEK293 cells. The cells were seeded at a density of 3 × 105 cells/cm2 on a polycarbonate membrane filter membrane on Transwell inserts (Millipore, Billerica, MA) and grown as monolayers for 5 days. Before starting the transport studies, the apical (A) and basolateral (B) chambers were washed twice with prewarmed HBSS, and then the cells were equilibrated for 30 minutes in the presence or absence of inhibitors MK-571 (20 μM) and TAK-875 (0–50 μM). HBSS containing the substrate vinblastine (Evers et al., 1998, 2000) was added to the donor side (either the apical or basolateral chamber), and the inhibitors were added to both chambers. The cells were incubated for 90 minutes at 37°C, at which time aliquots (150 μl) were collected from the donor and receiver chambers for analysis. The concentrations of vinblastine in both chambers were determined by LC-MS/MS.

Sample Preparation.

After cell lysis, 50 μl of cell lysate, 25 μl of the internal standard (10.0 ng/ml d5-atorvastatin or d5-TCA), and 150 μl of acetonitrile were added to centrifuge tubes. After vortex mixing and centrifugation at 14,000g for 5 minutes, the supernatants were injected into the LC-MS/MS system. Samples (25 μl) from the MDCK-MRP2 cells transport studies were added to a mixture of 25 μl of the internal standard vinorelbine (200 ng/ml) and 150 μl of acetonitrile, followed by vortex-mixing and centrifugation. The resultant supernatants were analyzed by LC-MS/MS.

LC-MS/MS Analysis.

The LC system consisted of LC-30AD pumps and a SIL-30AC autosampler (Shimadzu, Kyoto, Japan). For d8-TCA inhibition assay, the analyte was separated on SB C8 (150 mm × 4.6 mm i.d., 5 μm; Agilent Technologies, Santa Clara, CA) column. The mobile phase was 5 mM ammonium acetate-acetonitrile-ammonium hydroxide (40:60:0.0004, v/v/v) and was applied at a flow rate of 0.6 ml/min. A Luna C18 column (50 mm × 2.0 mm i.d., 5 μm; Phenomenex, Torrance, CA) was used for the chromatographic analysis of atorvastatin. The mobile phase was 10 mM ammonium acetate-acetonitrile-formic acid (40:60:0.0004, v/v/v) and was applied at a flow rate of 0.6 ml/min. In the bidirectional transport inhibition assay using MDCK-MRP2 cells, the analytes were separated on a Gemini C18 column (50 mm × 2.0 mm i.d., 5 μm; Phenomenex) and eluted by a mobile phase composed of (A) 10 mM ammonium acetate and 0.1% formic acid in water and (B) methanol (constant flow rate of 0.7 ml/min). The gradient conditions were as follows: 0–0.5 minutes, 40% B; 0.5–1.5 minutes, 40%–90% B; 1.5–2.5 minutes, 90% B; 2.5–2.6 minutes, return to 40% B; and 2.6–5.0 minutes re-equilibrium.

An AB Sciex Triple Quad 6500 system (Applied Biosystems, Concord, ON, Canada) fitted with a TurboIonSpray ion source was used for MS detection. Multiple reaction monitoring (MRM) was used to quantify compounds in the positive ion mode (m/z 559 → m/z 440 for atorvastatin; m/z 564 → m/z 445 for d5-atorvastatin; m/z 811.5 → m/z 224.2 for vinblastine; and m/z 779.5 → m/z 122 for the internal standard vinorelbine) or in the negative ion mode (m/z 522 → m/z 128 for d8-TCA and m/z 519 → m/z 124 for d5-TCA).

For simultaneous quantitation of 11 bile acids in rat serum, Shimadzu LC-20AD HPLC system coupled with an AB Sciex API 4000 triple quadrupole mass spectrometer was used. The analytes were separated on XDB C18 column (5.0 mm, 4.6 × 150 mm, Agilent) with gradient elution of 7.5 mM ammonium acetate (pH 4.0, A) and acetonitrile (B). The gradient conditions were as follows: 0–0.3 minutes, 30% B; 0.3–11 minutes, 30%–70% B; 11–14 minutes, 70%–100% B; 14–15 minutes, 100% B; 15–15.1 minutes, return to 30% B; and 15.1–19 minutes re-equilibrium. The flow rate was 0.8 ml/min. MRM was used to quantify compounds in the negative ion mode.

Data Analysis.

Accumulation in hepatocytes plus bile (standard buffer) and hepatocytes only (Ca2+-free buffer) was calculated as the amount of d8-TCA (in picomoles per well) divided by the protein content (milligrams of protein per well). The biliary excretion index (BEI) and the in vitro biliary clearance (CLbiliary) were calculated according to eq. 1 and eq. 2 (Liu et al., 1999a,b):

Embedded Image(1)Embedded Image(2)

The accumulation (standard and Ca2+-free buffer), BEI, and CLbiliary for d8-TCA were expressed as the percentage of the control value (no inhibitor).

The permeability coefficients of vinblastine (Papp,A to B and Papp,B to A) and the efflux ratio (ER) were calculated according to eq. 3 and eq. 4.Embedded Image(3)Embedded Image(4)where CT = the concentration of vinblastine on the receiver side, V = the loading volume on the receiver side, area = the surface area of the cell monolayer (0.33 cm2 in a 24-well plate), C0 = the initial concentration of vinblastine on the donor side, and t = incubation time. Papp,A to B and Papp,B to A represent the extent of permeation generated by the transport from the apical to basolateral sides and from the basolateral to apical sides, respectively.

All statistical analyses were performed using SPSS software (version 16.0 for Windows, SPSS Inc., Chicago, IL). Student’s two-tailed unpaired t test was used for between-group comparisons. A P value of < 0.05 was considered statistically significant.

Results

In Vivo Cholestatic Effects of TAK-875 in Rats.

We first investigated the direct interactions between TAK-875 and the serum ALT, ALP, AST, TBAs, and TBIL levels in rats to evaluate the potential cholestatic effects of TAK-875. As shown in Fig. 2, compared with the control group, the serum levels of ALT, ALP, and AST at 24 hours postdose were not significantly elevated at both doses. At the dose of 20 mg/kg of TAK-875, the serum TBAs levels and TBIL levels were comparable to the control within 8 hours postdose. However, the TBA levels were significantly increased 3 to 4 times within 0.25 hour to 4 hours after an intravenous administration of 100 mg/kg of TAK-875 and were almost back to baseline after approximately 8 hours postdose. The TBIL levels were increased 1.5 to 2.6 times within 0.25 to 8 hours after intravenous administration of 100 mg/kg TAK-875. The increase in the serum TBAs and TBIL was a fast response to administration of TAK-875.

Fig. 2.
Fig. 2.

Effects of TAK-875 on serum ALT, ALP, AST, TBA, and TBIL levels in rats. Rats were administered intravenous, either 20 mg/kg (solid squares) or 100 mg/kg (solid triangles) of TKA-875 or saline as control (solid circles). Blood samples were collected at indicated time points, and serum samples were analyzed using kits or biochemical analyzer. Data are expressed as the mean ± S.D. (n = 6). *P < 0.05, **P < 0.01, and ***P < 0.001 versus the control group.

The BAs, including TCA, CA, DCA, LCA, CDCA, UDCA, GCA, GCDCA, GDCA, GUDCA, and TCDCA, in rat serum were determined using LC-MS/MS (Table 1). The levels of TCA, CA, UDCA, and TCDCA in TAK-875 group were significantly increased (more than 2-fold) at 1 hour postdose compared with the predose level.

View this table:
TABLE 1

Changes of serum bile acids after a single intravenous dose of 100 mg/kg of TAK-875 to Sprague-Dawley rats (each group n = 6)

Effects of TAK-875 on the Hepatobiliary Disposition of d8-TCA in SCRH.

The effects of TAK-875 on the accumulation of d8-TCA were evaluated in SCRH (Fig. 3A). Coincubation with 10 μM CyA, a potent inhibitor of BSEP, significantly decreased the accumulation of d8-TCA in cells incubated in the standard buffer. Incubation with 20 or 100 μM TAK-875 significantly decreased the accumulation of d8-TCA in cells incubated in the standard and Ca2+-free buffers.

Fig. 3.
Fig. 3.

Inhibitory effects of TAK-875 on the accumulation, BEI, and CLbiliary of d8-TCA (1 μM) in SCRH. CyA (10 μM) was used as the positive inhibitor. (A) The accumulation of d8-TCA (1 μM) was measured in cells incubated in standard buffer (containing Ca2+, solid bar) or Ca2+-free buffer (open bar) for 10 minutes. (B) BEI and CLbiliary of d8-TCA in the presence of the indicated inhibitors expressed as percentages of the values in control cells. Data are shown as the mean ± S.D. (n = 3). **P < 0.01 and ***P < 0.001 versus control cells.

The effects of TAK-875 on the biliary efflux of d8-TCA were presented as BEI and CLbiliary. The data are shown as the percentage of the control (Fig. 3B). In the absence of inhibitors, the BEI for d8-TCA was 74.2%, indicating that 74.2% of the d8-TCA taken up by the hepatocytes was effluxed into bile. Incubation with 10 μM CyA reduced the BEI of d8-TCA to 23.8% of that of control cells. TAK-875 exhibited a concentration-dependent inhibitory effect in terms of the BEI of d8-TCA, with BEI values of 70% and 52% of control cells at TAK-875 concentrations of 20 μM and 100 μM, respectively. Both CyA (10 μM) and TAK-875 (20 μM and 100 μM) significantly decreased the CLbiliary of d8-TCA to <10% of control cells.

Effects of TAK-875 on Ntcp and Oatp/OATP Uptake Transporters.

The inhibitory effects of TAK-875 on the uptake of d8-TCA by Ntcp were investigated in primary rat hepatocytes. The uptake of d8-TCA was approximately 17.4 times greater in the presence of Na+ than in the absence of Na+, accounting for 93.9% of the total d8-TCA uptake (Fig. 4A). Ntcp-mediated uptake was defined as the difference in uptake between cells incubated in Na+-containing buffer and that in cells incubated in Na+-free buffer. The overall Na+-dependent uptake of d8-TCA by rat hepatocytes was inhibited by TAK-875 with a mean inhibitory concentration (IC50) of 10.9 ± 0.7 µM (Table 2; Fig. 4B).

Fig. 4.
Fig. 4.

(A) Inhibitory effects of TAK-875 on d8-TCA uptake into rat hepatocytes incubated in standard buffer (containing Na+, solid bar) or choline buffer (Na+-free, open bar). (B) Inhibitory effects of TAK-875 on Ntcp- and Oatp-mediated d8-TCA uptake into rat hepatocytes. Uptake was measured after incubating cells with 1 μM d8-TCA for 5 minutes. CyA (100 μM) was used as a positive control. Data are shown as the mean ± S.D. (n = 3).

View this table:
TABLE 2

Summary of IC50 values for TAK-875 inhibition on transporters in rats and human in vitro systems

TAK-875 inhibited Oatp-mediated d8-TCA uptake (in Na+-free buffer) in a concentration-dependent manner with an IC50 value of 2.94 ± 0.34 µM in primary rat hepatocytes (Table 2; Fig. 4B). The specific effects of TAK-875 on transport by OATP1B1 and OATP1B3 were then investigated using OATP1B1- and OATP1B3-expressing HEK293 cells. Atorvastatin was used as the surrogate probe substrate for OATP1B1 and OATP1B3. Significant inhibition of OATP-mediated atorvastatin uptake was observed in the presence of TAK-875 with IC50 values of 2.28 ± 0.17 µM and 3.98 ± 0.26 µM for OATP1B1 and OATP1B3, respectively (Table 2; Fig. 5).

Fig. 5.
Fig. 5.

Inhibitory effects of TAK-875 on atorvastatin uptake into HEK293 cells overexpressing OATP1B1 (A) or OATP1B3 (B). Uptake was measured after incubating cells with 0.3 μM atorvastatin for 2 minutes. OATP-mediated atorvastatin uptake was corrected by subtracting the nonspecific accumulation of atorvastatin in mock-transfected HEK293 cells from that in OATP-transfected cells. Data are shown as the mean ± S.D. (n = 3).

Inhibition of TAK-875 on the Mrp2/MRP2 Efflux Transporter.

CDFDA, a fluorescent bile acid analog, is hydrolyzed to CDF by esterase after its passive diffusion into hepatocytes. Then, CDF is primarily excreted into bile by MRP2/Mrp2 or effluxed back into blood by MRP3/Mrp3 (Zamek-Gliszczynski et al., 2003; Tian et al., 2004). Therefore, we examined the inhibitory effects of TAK-875 on Mrp2-mediated CDF accumulation in bile canaliculi using SCRHs (Fig. 6). The formation of a canalicular network was confirmed by fluorescent microscopy. The bright green spaces in Fig. 6A (small white arrows) indicate the formation of a canalicular space. MK-571, a known inhibitor of MRP2 and MRP3, and TAK-875 significantly decreased the fluorescent signal in the bile canaliculi, consistent with the inhibition of Mrp2. When administered at a high concentration, TAK-875 (100 µM) significantly increased the fluorescent signal throughout the entire microscopic field, indicating the enhanced accumulation of CDF in hepatocytes.

Fig. 6.
Fig. 6.

Inhibitory effects of TAK-875 on Mrp2-mediated accumulation of CDF in SCRHs. CDFDA (10 μM) passively diffuses into hepatocytes, where it is hydrolyzed to CDF and then effluxed into bile canaliculi via MRP2/Mrp2. CDF accumulation in bile canaliculi over 10 minutes was determined using an inverted fluorescent microscope. (A) Control cells. White arrows point to representative bile canaliculi. (B) Cells treated with the positive inhibitor 20 μM MK-571. (C) Cells treated with 20 μM TAK-875. (D) Cells treated with 100 μM TAK-875.

The inhibitory effects of TAK-875 on MRP2-mediated transport were also evaluated in MDCK-MRP2 cells using vinblastine as a substrate. The Papp,B to A of vinblastine was much greater (21.6 × 10−6 cm/s) than the Papp,A to B (0.38 × 10−6 cm/s), with an ER value of 56.8. The transport of vinblastine was markedly reduced by MK-571 (the ER was reduced to 5.6) and by the tested concentrations of TAK-875, indicating that these compounds inhibited MRP2-mediated transport of vinblastine. When using the reduction in the ER as an evaluation criterion, the estimated IC50 of TAK-875 for inhibiting MDCK-MRP2 cells was 2.41 ± 0.50 µM (Table 2; Fig. 7).

Fig. 7.
Fig. 7.

Inhibitory effects of TAK-875 on vinblastine transport in MDCK-MRP2 cells. Uptake was measured after incubating cells with 5 μM vinblastine for 90 minutes. Data are shown as the mean ± S.D. (n = 3).

Discussion

TAK-875 is a GPR40 agonist that was originally developed for the treatment of type 2 diabetes mellitus. However, its clinical development was unexpectedly terminated at phase III clinical trials because of liver safety concerns. Histopathological analysis revealed that compared with the normal architecture in control group, rats intravenously dosed with 100 mg/kg of TAK-875 exhibited picnotic nucleus in hepatocytes and mild bile duct dilation (Supplemental Fig. 3), indicating that TAK-875 could cause cholestatic liver injury. In this study, we examined the cholestatic effects of TAK-875 by measuring the acute changes in serum enzymes (ALT, ALP, and AST), TBAs, and TBIL concentrations after intravenous administration of TAK-875 to rats. We found that TAK-875 significantly increased the serum TBAs concentrations by 3 to 4 times compared with that in control rats, but did not change the serum levels of ALT, ALP, and AST, suggesting that TAK-875 disturbed the disposition of bile acids. Similar observations were reported with glyburide, CyA, and bosentan in rat serum (Funk et al., 2001b; Kostrubsky et al., 2003), which could cause cholestatic hepatitis in clinical settings. Considering the high accumulation of TAK-875 in liver, we speculate that TAK-875 may disturb bile acids transport, increasing the risk of hepatotoxicity. We further determined 11 BAs in rat serum at 1 hour postdose after a single intravenous dose of 100 mg/kg of TAK-875 using LC-MS/MS. The levels of CA, UDCA, TCDCA, and TCA were increased by greater than 2 times than those at predose.

Inhibition of the liver’s bile acid influx and efflux processes may cause marked changes in serum and hepatic bile acid concentrations. Because of the detergent-like properties of bile acids, an increase in the intracellular concentration of bile acids was associated with cellular necrosis and mitochondrial dysfunction during cholestasis (Maillette de Buy Wenniger and Beuers, 2010). Using d8-TCA as a probe for bile acid transport, we investigated the inhibitory effects of TAK-875 on the hepatobiliary disposition of d8-TCA in SCRHs. Of note, 20 μM TAK-875 significantly decreased the accumulation of d8-TCA in hepatocytes incubated in standard HBSS (representing hepatocytes plus bile) and hepatocytes incubated in Ca2+-free HBSS (representing hepatocytes only), leading to a decrease in the CLbiliary of d8-TCA to less than 10% of that in control cells. CLbiliary is an indicator of the overall effects of the compound on bile acids excretion. A decrease in CLbiliary can result from the inhibition of basolateral uptake transporters and/or canalicular efflux transporters.

The BEI represents the fraction of the total mass of d8-TCA taken up that is subsequently excreted into bile. The decreased BEI of d8-TCA in the presence of TAK-875 demonstrated that TAK-875 inhibited bile acids efflux into bile. Considering that TCA is secreted primarily into the canaliculus via Bsep, the inhibitory effects on d8-TCA efflux by TAK-875 may be associated with the inhibition of Bsep. Many BSEP inhibitors, including troglitazone, bosentan, and glyburide, have been identified and are associated with drug-induced cholestatic hepatotoxicity (Fattinger et al., 2001; Smith, 2003). Although hepatotoxicity signals were not observed during the preclinical testing of troglitazone (Yang et al., 2014), in vitro and in vivo studies in rats demonstrated that troglitazone and its sulfate metabolite inhibited bile acids efflux by interfering with Bsep, and this interaction may contribute to troglitazone-induced hepatotoxicity in humans (Funk et al., 2001a; Funk et al., 2001b).

The decrease in the accumulation of d8-TCA in SCRH in standard buffer to 28.7% of that in control cells suggests that TAK-875 inhibits bile acids influx into hepatocytes. Because the accumulation of d8-TCA was inhibited to a greater extent than BEI, it seems that TAK-875 has a greater effect on hepatic bile acids uptake than on biliary bile acids efflux at the concentrations tested in rat hepatocytes. Bosentan and troglitazone exhibited similar effects on the hepatobiliary disposition of d8-TCA in SCRH, as observed for TAK-875 (Ansede et al., 2010). However, CyA caused significant decreases in both BEI and CLbiliary, suggesting that efflux processes were inhibited to a greater extent than the uptake processes. These results are consistent with earlier observations (Ansede et al., 2010). Uptake of bile acids into hepatocytes is mediated in an Na+-dependent manner by NTCP (predominant route) and an Na+-independent manner by OATP (minor route). To identify the mechanisms underlying the inhibitory effects of TAK-875 on the uptake of d8-TCA, we further investigated the effects of TAK-875 on the transporters Ntcp and Oatps/OATPs. TAK-875 exhibited more potent inhibitory effects on Oatps than on Ntcp, with IC50 values of 2.94 μM and 10.9 μM, respectively. The main liver OATP families in humans are OATP1B1 and OATP1B3 and in rats are Oatp1a1, Oatp1a4, and Oatp1b2 (Meier-Abt et al., 2004; Klaassen and Aleksunes, 2010). TAK-875 inhibited the transporters OATP1B1 and OATP1B3 with comparable IC50 values to Oatps overall.

The inhibition of NTCP could be regarded as a hepatoprotective mechanism because it reduces TBAs accumulation in hepatocytes. Bosentan exhibited hepatotoxicity in clinical settings but was not hepatotoxic in rats, a phenomenon that was attributed to its more potent inhibitory effects of rat Ntcp (IC50 0.71 μM) than human NTCP (IC50 24 μM) (Leslie et al., 2007). Thus, the differential inhibition of NTCP in rats or humans could explain the species differences in the susceptibility to drug-induced hepatotoxicity. Our results also suggest that TAK-875 impairs d8-TCA uptake, primarily by inhibiting Ntcp, which may be a hepatoprotective mechanism in rats. Hence, if TAK-875 inhibits human NTCP to a lesser extent than rat Ntcp or does not inhibit human NTCP, bile acids are likely to be highly accumulated in human hepatocytes through the inhibition of BSEP, increasing the likelihood of cholestatic hepatotoxicity.

The increase of serum TBIL in rats after an intravenous administration of 100 mg/kg TAK-875 also indicated that the transport of bilirubin was disturbed. Bilirubin is another potentially cytotoxic endogenous substance associated with severe liver injury. It was reported that biliary excretion is the rate-limiting step of bilirubin elimination. At high intracellular concentrations, bilirubin can uncouple oxidative phosphorylation, reduce DNA stability, interrupt protein synthesis, and block ATPase activity in brain mitochondria (Hansen, 2001). Therefore, hyperbilirubinemia may provide an early warning of possible adverse effects, such as neurotoxicity and hepatotoxicity. Bilirubin is taken up into hepatocytes via OATPs and is then excreted into bile via MRP2 (the primary route) or into plasma via MRP3 (a compensatory route) in the form of bilirubin glucuronides (Jedlitschky et al., 1997; Cui et al., 2001; Keppler, 2014). We found that TAK-875 is a strong inhibitor of OATP1B1 and OATP1B3, which suggests that TAK-875 may increase the serum concentration of unconjugated bilirubin. Indeed, in vitro, inhibition of OATP1B1 and/or OATP1B3 is associated with clinical unconjugated hyperbilirubinemia observed with several drugs, including atazanavir, indinavir, amprenavir, saquinavir, CyA, and rifampicin SV (Campbell et al., 2004; Annaert et al., 2010; Chiou et al., 2014). Furthermore, drugs that interfere with MRP2, which directly regulates the biliary excretion of bilirubin glucuronides, may contribute to clinical hyperbilirubinemia (Chang et al., 2013). When using CDF as the probe substrate of Mrp2 in the SCRH, TAK-875 significantly decreased the accumulation of CDF in bile canaliculi and increased its accumulation in hepatocytes, which indicates that TAK-875 is a potently inhibitor of Mrp2. The results of our in vitro studies using MDCK-MRP2 cells further confirmed the inhibitory effects of TAK-875 on MRP2. Therefore, by simultaneously inhibiting MRP2 and OATP1B1/3, TAK-875 may cause a marked increase in bilirubin concentrations, an event that may contribute to liver problems. In addition, impaired bile acids excretion slows bile flow, decreases biliary excretion of conjugated bilirubin, and increases bilirubin accumulation in hepatocytes (Hofmann, 1999). It was also reported that the expression of MRP2 is downregulated in cholestatic conditions (Trauner et al., 1997), which might further disrupt the elimination of bilirubin and aggravate hyperbilirubinemia.

Because TAK-875 can reach high concentrations in the liver, it might cause cholestatic hepatotoxicity and/or hyperbilirubinemia by potently inhibiting the hepatobiliary disposition of bile acids and bilirubin (Fig. 8). Diabetic patients might therefore have a higher risk of hepatotoxicity as a result of the slower elimination rate and higher accumulation of TAK-875 (Leifke et al., 2012). Several transporters, including OATPs, MRPs, NTCP, and BSEP, are known to be polymorphic, and genetic mutations that alter the interactions between TAK-875 and either of these proteins could lead to the interindividual differences in susceptibility to TAK-875–induced hepatotoxicity.

Fig. 8.
Fig. 8.

Schema showing the potential mechanisms by which TAK-875 affects the major hepatobiliary transport pathways of bile acids and bilirubin.

The rat model evaluated only the effects of TAK-875 on ALT, AST, ALP, TBA, and TBIL levels after a single administration of TAK-875 and may not be representative of drug-induced liver injury in humans which arose after long-term administration. The plasma protein binding of TAK-875 was high (>99%); thus, the unbound plasma concentrations were markedly lower than the IC50 values of evaluated transporters. Despite this difference, significant elevations of TBAs and TBIL levels in rat serum were observed and were speculated to be caused by the inhibition of transporters.

Overall, our observation that TAK-875 is an inhibitor of several hepatobiliary transporters, namely, MRP2, NTCP, and OATP, may provide a possible mechanism of TAK-875-induced liver injury. Our results also highlight the importance of hepatobiliary transporters in drug discovery and development.

Acknowledgments

The authors thank Dr. Xiaoyan Pang (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) for helpful discussions.

Authorship Contributions

Participated in research design: Li, K. Zhong, Chen.

Conducted experiments: Li, K. Zhong, Guo.

Contributed new reagents or analytic tools: Li, K. Zhong, Chen.

Performed data analysis: Li, K. Zhong, Chen.

Contributed to the writing of the manuscript: Li, K. Zhong, Chen, D. Zhong.

Footnotes

    • Received March 3, 2015.
    • Accepted August 12, 2015.

  • Xiuli Li and Kan Zhong contributed equally to this work.

  • This work was supported by the National Natural Science Foundation of China [81173115 and 81173117].

  • dx.doi.org/10.1124/dmd.115.064121.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

Abbreviations

ALP
alkaline phosphatase
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BEI
biliary excretion index
BSEP
bile salt export pump
CA
cholic acid
CDCA
chenodeoxycholic acid
CDF
5 (and 6)-carboxy-2′,7′-dichlorofluorescein
CDFDA
5 (and 6)-carboxy-2′,7′-dichlorofluorescein diacetate
CLbiliary
biliary clearance
CyA
cyclosporine A
DCA
deoxycholic acid
ER
efflux ratio
GCA
glycocholic acid
GCDCA
glycochenodeoxycholic acid
GDCA
glycodeoxycholic acid
GPR 40
G-protein–coupled receptor 40
GUDCA
glycoursodeoxycholic acid
HBSS
Hanks’ balanced salt solution
HEK293
human embryonic kidney cells
HPLC
high-performance liquid chromatography
LCA
lithocholic acid
LC-MS/MS
liquid chromatography-tandem mass spectrometry
MDCK
Madin-Darby canine kidney cells
MRP2
multidrug resistance-associated protein 2
NTCP
Na+-taurocholate cotransporting polypeptide
NTCP
Na+-taurocholate co-transporting polypeptide
OATP
organic anion transporting polypeptide
SCRH
sandwich-cultured rat hepatocytes
TBA
total bile acid
TBIL
total bilirubin
TCA
taurocholic acid
TCDCA
taurochenodeoxycholic acid
UDCA
ursodeoxycholic acid

References

  1. ↵
    1. Alrefai WA and
    2. Gill RK
    (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24:1803–1823.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Annaert P,
    2. Ye ZW,
    3. Stieger B, and
    4. Augustijns P
    (2010) Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163–176.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Annaert PP,
    2. Turncliff RZ,
    3. Booth CL,
    4. Thakker DR, and
    5. Brouwer KL
    (2001) P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab Dispos 29:1277–1283.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Ansede JH,
    2. Smith WR,
    3. Perry CH,
    4. St Claire RL 3rd., and
    5. Brouwer KR
    (2010) An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes. Drug Metab Dispos 38:276–280.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Campbell SD,
    2. de Morais SM, and
    3. Xu JJ
    (2004) Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 150:179–187.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Chang JH,
    2. Plise E,
    3. Cheong J,
    4. Ho Q, and
    5. Lin M
    (2013) Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm 10:3067–3075.
    OpenUrlCrossRef
  7. ↵
    1. Chiou WJ,
    2. de Morais SM,
    3. Kikuchi R,
    4. Voorman RL,
    5. Li X, and
    6. Bow DA
    (2014) In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia. Xenobiotica 44:276–282.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Cui Y,
    2. König J,
    3. Leier I,
    4. Buchholz U, and
    5. Keppler D
    (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–9630.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Dawson PA,
    2. Lan T, and
    3. Rao A
    (2009) Bile acid transporters. J Lipid Res 50:2340–2357.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Evers R,
    2. de Haas M,
    3. Sparidans R,
    4. Beijnen J,
    5. Wielinga PR,
    6. Lankelma J, and
    7. Borst P
    (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83:375–383.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Evers R,
    2. Kool M,
    3. van Deemter L,
    4. Janssen H,
    5. Calafat J,
    6. Oomen LC,
    7. Paulusma CC,
    8. Oude Elferink RP,
    9. Baas F,
    10. Schinkel AH,
    11. et al.
    (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310–1319.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Fattinger K,
    2. Funk C,
    3. Pantze M,
    4. Weber C,
    5. Reichen J,
    6. Stieger B, and
    7. Meier PJ
    (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Funk C,
    2. Pantze M,
    3. Jehle L,
    4. Ponelle C,
    5. Scheuermann G,
    6. Lazendic M, and
    7. Gasser R
    (2001a) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167:83–98.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Funk C,
    2. Ponelle C,
    3. Scheuermann G, and
    4. Pantze M
    (2001b) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627–635.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Hansen TW (2001) Bilirubin brain toxicity. J Perinatol 21(Suppl 1):S48–S62.
  16. ↵
    1. Hofmann AF
    (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159:2647–2658.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Jacquemin E,
    2. Hagenbuch B,
    3. Stieger B,
    4. Wolkoff AW, and
    5. Meier PJ
    (1994) Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci USA 91:133–137.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Jedlitschky G,
    2. Leier I,
    3. Buchholz U,
    4. Hummel-Eisenbeiss J,
    5. Burchell B, and
    6. Keppler D
    (1997) ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327:305–310.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Keppler D
    (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561–565.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Klaassen CD and
    2. Aleksunes LM
    (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1–96.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Köck K and
    2. Brouwer KL
    (2012) A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 92:599–612.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Kostrubsky VE,
    2. Strom SC,
    3. Hanson J,
    4. Urda E,
    5. Rose K,
    6. Burliegh J,
    7. Zocharski P,
    8. Cai H,
    9. Sinclair JF, and
    10. Sahi J
    (2003) Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220–228.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Leifke E,
    2. Naik H,
    3. Wu J,
    4. Viswanathan P,
    5. Demanno D,
    6. Kipnes M, and
    7. Vakilynejad M
    (2012) A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin Pharmacol Ther 92:29–39.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Leslie EM,
    2. Watkins PB,
    3. Kim RB, and
    4. Brouwer KL
    (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170–1178.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Li C,
    2. Zhang L,
    3. Zhou L,
    4. Wo SK,
    5. Lin G, and
    6. Zuo Z
    (2012) Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae. AAPS J 14:23–34.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Liu X,
    2. Chism JP,
    3. LeCluyse EL,
    4. Brouwer KR, and
    5. Brouwer KL
    (1999a) Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637–644.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Liu X,
    2. LeCluyse EL,
    3. Brouwer KR,
    4. Gan LS,
    5. Lemasters JJ,
    6. Stieger B,
    7. Meier PJ, and
    8. Brouwer KL
    (1999b) Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am J Physiol 277:G12–G21.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Maillette de Buy Wenniger L and
    2. Beuers U
    (2010) Bile salts and cholestasis. Dig Liver Dis 42:409–418.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Mayer M,
    2. Nudurupati S,
    3. Peng X, and
    4. Marcinak J
    (2014) Evaluation of the pharmacokinetics and safety of a single oral dose of fasiglifam in subjects with normal or varying degrees of impaired renal function. Drugs R D 14:273–282.
    OpenUrlCrossRef
  30. ↵
    1. Meier-Abt F,
    2. Faulstich H, and
    3. Hagenbuch B
    (2004) Identification of phalloidin uptake systems of rat and human liver. Biochim Biophys Acta 1664:64–69.
    OpenUrlPubMed
  31. ↵
    1. Meier PJ,
    2. Eckhardt U,
    3. Schroeder A,
    4. Hagenbuch B, and
    5. Stieger B
    (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667–1677.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Naik H,
    2. Vakilynejad M,
    3. Wu J,
    4. Viswanathan P,
    5. Dote N,
    6. Higuchi T, and
    7. Leifke E
    (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52:1007–1016.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Negoro N,
    2. Sasaki S,
    3. Mikami S,
    4. Ito M,
    5. Suzuki M,
    6. Tsujihata Y,
    7. Ito R,
    8. Harada A,
    9. Takeuchi K,
    10. Suzuki N,
    11. et al.
    (2010) Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1:290–294.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Satlin LM,
    2. Amin V, and
    3. Wolkoff AW
    (1997) Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem 272:26340–26345.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Smith MT
    (2003) Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 16:679–687.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Tian X,
    2. Zamek-Gliszczynski MJ,
    3. Zhang P, and
    4. Brouwer KL
    (2004) Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol Pharmacol 66:1004–1010.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Trauner M,
    2. Arrese M,
    3. Soroka CJ,
    4. Ananthanarayanan M,
    5. Koeppel TA,
    6. Schlosser SF,
    7. Suchy FJ,
    8. Keppler D, and
    9. Boyer JL
    (1997) The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 113:255–264.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Trauner M and
    2. Boyer JL
    (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633–671.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Yang K,
    2. Woodhead JL,
    3. Watkins PB,
    4. Howell BA, and
    5. Brouwer KL
    (2014) Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 96:589–598.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Zamek-Gliszczynski MJ,
    2. Hoffmaster KA,
    3. Tweedie DJ,
    4. Giacomini KM, and
    5. Hillgren KM
    (2012) Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther 92:553–556.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Zamek-Gliszczynski MJ,
    2. Xiong H,
    3. Patel NJ,
    4. Turncliff RZ,
    5. Pollack GM, and
    6. Brouwer KL
    (2003) Pharmacokinetics of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304:801–809.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

TAK-875 Inhibits Hepatobiliary Transporters

Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong and Xiaoyan Chen
Drug Metabolism and Disposition November 1, 2015, 43 (11) 1751-1759; DOI: https://doi.org/10.1124/dmd.115.064121
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement